Fmoc-L-isoleucine (CAS 71989-23-6, molecular weight 353.41 g/mol) functions as the N-α-Fmoc-protected isoleucine building block for solid-phase peptide synthesis on bench-scale and pilot-scale resin loading systems. In a standard Fmoc strategy on low-loading Rink amide AM resin with substitution 0.3–0.5 mmol/g, the resin is swollen in N,N-dimethylformamide for 30 minutes at 20–25°C before the first cycle. The N-terminal Fmoc group is removed using 20% piperidine in DMF in two stages of 5 minutes and 10 minutes, followed by three DMF washes. Fmoc-L-isoleucine is activated as a 0.3 M DMF solution. A 3-fold molar excess over the free amino groups is combined with 2.85 equivalents of HATU and 6 equivalents of N,N-diisopropylethylamine. The activated solution is transferred immediately to the resin. Coupling is maintained under nitrogen agitation for 45–60 minutes at 20–25°C. Because the isoleucine side chain is β-branched, the activated carboxyl carbon is sterically shielded more than in leucine or valine. Quantitative coupling at hindered positions commonly requires a second fresh coupling cycle using the same 3-fold excess but with a shortened contact time of 30 minutes. Automated microwave synthesizers may execute the second coupling at 45°C using a 0.5 M coupling solution to compensate for reduced diffusion inside the swollen resin. Washing after coupling uses DMF and dichloromethane, each three times. A Kaiser test is performed after each isoleucine coupling. A positive Kaiser result triggers immediate recoupling rather than capping, because capping at an isoleucine deletion site creates a truncated peptide impurity that can co-elute with the target in reverse-phase HPLC. After chain assembly, the peptide resin is dried under vacuum and cleaved with TFA/triisopropylsilane/water in a 95:2.5:2.5 volume ratio for 2.5 hours at 20–25°C. The crude peptide is precipitated in cold methyl tert-butyl ether, centrifuged, and washed twice with ether. The precipitate is redissolved in 10% aqueous acetonitrile with 0.1% TFA and lyophilized. The terminal product is a linear peptide bearing the intended isoleucine residue. Incorporation is confirmed by LC-MS and by amino acid analysis after acid hydrolysis with 6 M HCl at 110°C for 24 hours. This research-grade route produces peptides for in vitro binding assays and solubility screening, not for direct human use.

Why Does GMP Release of Fmoc-L-isoleucine Require Chiral Purity and Residual Solvent Control?

Fmoc-L-isoleucine used in GMP peptide active pharmaceutical ingredient manufacturing is purchased under a supplier quality system aligned with ICH Q7. The release documentation includes appearance, specific optical rotation, HPLC purity, chiral purity, water by Karl Fischer titration, residual solvents according to ICH Q3C and USP <467>, and elemental impurities according to ICH Q3D. A typical purchase specification sets chromatographic purity at ≥99.0% by HPLC at 220 nm, combined D-isoleucine and D-allo-isoleucine at ≤0.5% by chiral HPLC, water at ≤0.5%, and total residual solvents within class-specific concentration limits. DMF and dichloromethane are the most frequently monitored residual solvents because the manufacturing route uses these media for N-protection and crystallization. At peptide assembly scale, Fmoc-L-isoleucine is dissolved as a 0.3 M DMF solution and is activated with 2.9 equivalents of TBTU, 2.9 equivalents of HOBt, and 6 equivalents of DIPEA. The coupling slurry is transferred to a jacketed SPPS column reactor with a sintered frit and nitrogen agitation. Coupling proceeds for 40–60 minutes at 20–25°C. The resin is washed with DMF and dichloromethane. Incomplete coupling at isoleucine positions is corrected by a second coupling with a fresh 2-fold excess of activated Fmoc-L-isoleucine rather than by extending exposure to DIPEA. Extended base treatment at room temperature can promote α-carbon deprotonation and increase D-isoleucine-related impurities in the assembled peptide. The terminal peptide resin is cleaved with TFA/triisopropylsilane/water in a 95:2.5:2.5 volume ratio for 2–3 hours at 20–25°C. The crude peptide is precipitated in cold methyl tert-butyl ether and purified by preparative reverse-phase HPLC using C18 bonded silica and a mobile phase containing 0.1% TFA. If the final drug substance must be an acetate salt, the preparative HPLC pool is passed through an ion exchange column equilibrated with acetic acid. The terminal product is a lyophilized peptide API with defined counterion content. Release testing includes HPLC purity, peptide content by nitrogen analysis or UV, counterion assay, residual TFA by ion chromatography, residual solvents by headspace gas chromatography, and mass identity by electrospray ionization mass spectrometry. Fmoc-L-isoleucine should be stored at −20°C in a desiccated, airtight container under nitrogen. The free acid form is stable under these conditions; however, preactivated solutions in DMF should be used immediately and never stored for the next production batch.

In parallel peptide library construction, Fmoc-L-isoleucine is distributed as a 0.2 M stock solution in N-methyl-2-pyrrolidone to automated 48- or 96-channel synthesizer modules. The activation chemistry uses DIC and Oxyma at 4 equivalents relative to the resin-bound free amine. Coupling is performed for 30 minutes at 40°C. Because isoleucine is β-branched, every isoleucine position is programmed for double coupling by default. The second coupling uses an additional 4 equivalents of Fmoc-L-isoleucine and fresh DIC/Oxyma. Single-coupling protocols at isoleucine positions produce deletion impurities that are difficult to remove from later crude libraries by reversed-phase fractionation. Stock solutions of Fmoc-L-isoleucine in NMP are prepared daily because aged solutions can deposit solids in the synthesizer transfer lines and cause channel-to-channel variability in peptide content. The assembled peptide libraries are cleaved from the resin with TFA/triisopropylsilane/water in a 95:2.5:2.5 volume ratio for 2 hours at 20–25°C. The crude peptides are precipitated in cold methyl tert-butyl ether and lyophilized from 0.1% TFA in aqueous acetonitrile. Library peptides are typically 8–20 residues. Crude purity ranges from 60% to 90% by RP-HPLC at 214 nm, depending on peptide length and the number of isoleucine residues. The terminal products are research-use-only linear peptides for primary screening in receptor-binding, enzyme-inhibition, or antimicrobial assays. No drug substance release documentation is generated. Process experience on multi-channel synthesizers indicates that the single largest source of batch-to-batch variability at isoleucine positions is not the coupling chemistry but delayed transfer of the activated amino acid solution after DIPEA addition. Therefore, the automated protocol adds DIPEA separately to the resin reaction vessel immediately before the Fmoc-L-isoleucine/DIC/Oxyma premix is delivered. This sequence reduces premature active ester hydrolysis.

Peptide Conjugate Synthesis via Orthogonal Lys and Cys Protection

Fmoc-L-isoleucine is incorporated into protected peptide segments that are required to carry orthogonal conjugation handles at Lys or Cys after chain assembly. The solid support is 2-chlorotrityl chloride resin loaded at 0.4–0.8 mmol/g. The Fmoc-L-isoleucine coupling uses 2.5–3 equivalents of the amino acid, 2.4–2.9 equivalents of N,N′-diisopropylcarbodiimide, and 2.5–2.9 equivalents of HOBt in DMF. The reaction proceeds for 60 minutes at 20–25°C. A second coupling with a fresh 2-fold excess is applied when the isoleucine is located next to a sterically demanding pseudoproline or N-methylated residue. The terminal product of the solid-phase assembly is a fully protected peptide resin retaining tert-butyl, trityl, Pbf, and Boc side-chain protection. The protected peptide can be obtained by mild cleavage from 2-chlorotrityl chloride resin using 20% hexafluoroisopropanol in DCM for 30–60 minutes. This produces a protected peptide segment for solution-phase conjugation or fragment condensation. In the alternative on-resin route, an orthogonal Lys(Mtt) handle is removed with 1% TFA in DCM containing 5% triisopropylsilane for 10–30 minutes. The exposed ε-amino group is acylated with a linker such as 6-maleimidocaproic acid or a PEG spacer bearing an activated ester. The Fmoc-L-isoleucine residue remains unchanged during this selective deprotection. The final peptide-linker intermediate is then cleaved from the resin with TFA/triisopropylsilane/water and purified by preparative HPLC. Terminal products include maleimide-functionalized peptide-linker intermediates intended for conjugation to monoclonal antibodies or carrier proteins. Purified fractions are lyophilized as TFA salts. The purchaser should specify residual maleimidocaproic acid and DMF levels in the release specification because these impurities can compete in downstream conjugation. Elemental impurities are controlled according to ICH Q3D as part of vendor qualification.

When Peptide Epitopes Require Scavenger-Modified Cleavage and Acetate Counterion Exchange

For 15–30 residue peptide epitopes containing isoleucine, Fmoc-L-isoleucine is introduced at a 5-fold molar ratio using HATU and DIPEA at 6 equivalents in DMF. The support is Rink amide AM resin at 0.3–0.5 mmol/g. Coupling is carried out for 45–60 minutes at 20–25°C. The incorporation of isoleucine near the N-terminal region of the epitope is monitored by electrospray mass spectrometry of a small resin aliquot after TFA microcleavage. The full peptide is cleaved with TFA/triisopropylsilane/water/1,2-ethanedithiol in a 94:2.5:2.5:1 volume ratio for 2.5 hours. The addition of ethanedithiol as a scavenger limits alkylation of the isoleucine-containing peptide by reactive carbocations released from side-chain deprotection. The crude peptide is precipitated and washed in cold methyl tert-butyl ether. Purification uses preparative C18 HPLC with a linear gradient from 0.1% TFA in water to 0.1% TFA in acetonitrile. Product fractions with purity greater than 95% by analytical HPLC at 214 nm are pooled and lyophilized. The terminal product is a purified peptide amide for preclinical enzyme-linked immunosorbent assay or T-cell stimulation experiments. If material is destined for in vivo challenge, the TFA salt is exchanged to acetate by ion exchange or by repeated lyophilization from 0.1 M acetic acid. Residual TFA is measured by ion chromatography. Endotoxin levels are not controlled during standard SPPS and must be addressed by the end user through depyrogenation of vessels and water used for final dissolution. Structural identity of the isoleucine residue in the final epitope is confirmed by amino acid analysis after acid hydrolysis and by tandem mass spectrometry.